Theravance Biopharma, Inc. (NASDAQ:TBPH) Sees Significant Increase in Short Interest

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,460,000 shares, an increase of 25.3% from the August 15th total of 3,560,000 shares. Based on an average daily volume of 333,700 shares, the short-interest ratio is presently 13.4 days. Approximately 9.6% of the company’s stock are short sold. Approximately 9.6% of the company’s stock are short sold. Based on an average daily volume of 333,700 shares, the short-interest ratio is presently 13.4 days.

Theravance Biopharma Stock Up 1.3%

Theravance Biopharma stock opened at $14.05 on Thursday. The business has a 50 day moving average price of $12.56 and a two-hundred day moving average price of $10.69. The stock has a market cap of $707.56 million, a price-to-earnings ratio of 58.54 and a beta of 0.05. Theravance Biopharma has a 12 month low of $7.88 and a 12 month high of $14.55.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on TBPH shares. Jones Trading upgraded shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, June 17th. BTIG Research boosted their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, June 27th. B. Riley began coverage on Theravance Biopharma in a research report on Friday, September 12th. They set a “buy” rating and a $28.00 price objective for the company. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday. Finally, Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $23.00.

Insider Activity

In related news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction on Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares of the company’s stock, valued at approximately $3,723,596.02. The trade was a 2.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 3,281 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma in the 1st quarter worth approximately $101,000. R Squared Ltd raised its holdings in shares of Theravance Biopharma by 636.6% in the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 10,822 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new position in Theravance Biopharma during the fourth quarter worth $119,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.